Holen Sie sich die Stockscreener-App
0.6654
2.37%
0.0154
Handel nachbörslich:
.65
-0.0154
-2.31%
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Gets Attention with GLP-1 Test on Deck - Bez Kabli
LEXX Should I Buy - Intellectia AI
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
MarketsMedicine Hat News - FinancialContent
TradingKey - TradingKey
lxrp_ex991.htm - SEC.gov
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
What Lexaria's CEO says is next for GLP-1 research in 2026 - Stock Titan
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com India
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network
Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan
Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus
Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa
Lexaria extends pharma partnership to evaluate GLP-1 technology - Investing.com
Lexaria's pharma license stays active as 3 GLP-1 studies continue - Stock Titan
Lexaria's Human GLP-1 Study #5 Begins Dosing - 富途牛牛
Fit to Work: GLP-1 and Metabolic Health in the M&A Sector - Investing News Network
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - The Facts
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - The Facts
Lexaria Bioscience (LEXX) Advances Research with New Animal Stud - GuruFocus
Lexaria's 18-arm test will compare pills and capsules for two GLP-1 drugs - Stock Titan
Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications - Investing News Network
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):